<DOC>
	<DOCNO>NCT01100359</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , liposome-encapsulated doxorubicin citrate carboplatin , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well liposome-encapsulated doxorubicin citrate give together carboplatin work treat patient advanced metastatic recurrent endometrial cancer .</brief_summary>
	<brief_title>Liposome-Encapsulated Doxorubicin Citrate Carboplatin Treating Patients With Advanced Metastatic Recurrent Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess activity combination liposome-encapsulated doxorubicin citrate carboplatin patient primary advance metastatic recurrent carcinoma endometrium . Secondary - To assess toxicity feasibility regimen patient . - To determine progression-free survival overall survival patient . OUTLINE : This multicenter study . Patients receive liposome-encapsulated doxorubicin citrate IV 1 hour follow carboplatin IV 30 minute day 1 . Treatment repeat every 21 day 6-9 course absence disease progression unacceptable toxicity . Tissue array immunohistochemistry analysis conduct paraffin-embedded tumor block primarily operate tissue patient different marker ( e.g. , progesterone-/estrogen receptor , HER2-receptor , soluble L1-molecule , Topo 2a ) examine tumor characteristic . Quality life assess baseline , study treatment , completion study treatment , 1 year completion study treatment . After completion study therapy , patient follow every 3 month 1 year .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis endometrial carcinoma , include follow cellular type : Mixed Mullerian carcinoma Serous carcinoma Clear cell carcinoma Primary advance ( FIGO stage III stage IV ) metastatic recurrent disease Disease curable surgery Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm xray , physical exam , nonspiral CT scan OR ≥ 10 mm spiral CT scan MRI No known cerebral metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 12 week Platelet count ≥ 100,000/mm^3 ANC ≥ 1,500/mm^3 Hemoglobin ≥ 10 g/dL Creatinine ≤ 1.25 time upper limit normal ( ULN ) Bilirubin ≤ 1.25 time ULN AST/ALT &lt; 3 time ULN Glomerular filtration rate ≥ 50 mL/min LVEF ≥ 50 % ECHO Fertile patient must use effective contraception No myocardial infarction within past 6 month No NYHA class IIIV congestive heart failure No third degree complete heart block unless pacemaker place No malignancy within past 5 year No concomitant medical illness ( e.g. , uncontrolled infection , uncontrolled angina , relevant illness ) make prescribed treatment within study unfeasible No known hypersensitivity study drug No psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule PRIOR CONCURRENT THERAPY : No prior chemotherapy disease recurrence At least 12 month since prior adjuvant therapy contain anthracyclines cumulative dos exceed follow : Epirubicin 600 mg/m² Doxorubicin 300 mg/m² At least 6 month since prior adjuvant therapy contain platinum At least 4 week since completion radiotherapy involve whole pelvis No concurrent radiotherapy plan radiotherapy study No concurrent endocrine , immunological , anticancer therapy No concurrent participation another investigational drug study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>endometrial clear cell carcinoma</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>stage IIIA endometrial carcinoma</keyword>
	<keyword>stage IIIB endometrial carcinoma</keyword>
	<keyword>stage IIIC endometrial carcinoma</keyword>
	<keyword>stage IVA endometrial carcinoma</keyword>
	<keyword>stage IVB endometrial carcinoma</keyword>
</DOC>